Barr J, Egan T D, Sandoval N F, Zomorodi K, Cohane C, Gambus P L, Shafer S L
Department of Anesthesia, Stanford University, VA Palo Alto Health Care System, California 94304, USA.
Anesthesiology. 2001 Aug;95(2):324-33. doi: 10.1097/00000542-200108000-00011.
The pharmacology of propofol infusions administered for long-term sedation of intensive care unit (ICU) patients has not been fully characterized. The aim of the study was to develop propofol dosing guidelines for ICU sedation based on an integrated pharmacokinetic-pharmacodynamic model of propofol infusions in ICU patients.
With Institutional Review Board approval, 30 adult male medical and surgical ICU patients were given target-controlled infusions of propofol for sedation, adjusted to maintain a Ramsay sedation scale score of 2-5. Propofol administration in the first 20 subjects was based on a previously derived pharmacokinetic model for propofol. The last 10 subjects were given propofol based on a pharmacokinetic model derived from the first 20 subjects. Plasma propofol concentrations were measured, together with sedation score. Population pharmacokinetic and pharmacodynamic parameters were estimated by means of nonlinear regression analysis in the first 20 subjects, then prospectively tested in the last 10 subjects. An integrated pharmacokinetic-pharmacodynamic model was used to construct dosing regimens for light and deep sedation with propofol in ICU patients.
The pharmacokinetics of propofol were described by a three-compartment model with lean body mass and fat body mass as covariates. The pharmacodynamics of propofol were described by a sigmoid model, relating the probability of sedation to plasma propofol concentration. The pharmacodynamic model for propofol predicted light and deep levels of sedation with 73% accuracy. Plasma propofol concentrations corresponding to the probability modes for sedation scores of 2, 3, 4, and 5 were 0.25, 0.6, 1.0, and 2.0 microg/ml. Predicted emergence times in a typical subject after 24 h, 72 h, 7 days, and 14 days of light sedation (sedation score = 3 --> 2) with propofol were 13, 34, 198, and 203 min, respectively. Corresponding emergence times from deep sedation (sedation score = 5 --> 2) with propofol were 25, 59, 71, and 74 h.
Emergence time from sedation with propofol in ICU patients varies with the depth of sedation, the duration of sedation, and the patient's body habitus. Maintaining a light level of sedation ensures a rapid emergence from sedation with long-term propofol administration.
用于重症监护病房(ICU)患者长期镇静的丙泊酚输注药理学尚未完全明确。本研究的目的是基于ICU患者丙泊酚输注的整合药代动力学-药效学模型制定ICU镇静的丙泊酚给药指南。
经机构审查委员会批准,对30例成年男性内科和外科ICU患者给予丙泊酚靶控输注进行镇静,调整剂量以维持 Ramsay 镇静评分在2 - 5分。前20例受试者的丙泊酚给药基于先前推导的丙泊酚药代动力学模型。后10例受试者的丙泊酚给药基于从前20例受试者推导的药代动力学模型。测量血浆丙泊酚浓度以及镇静评分。在前20例受试者中通过非线性回归分析估计群体药代动力学和药效学参数,然后在后10例受试者中进行前瞻性测试。使用整合药代动力学-药效学模型构建ICU患者丙泊酚浅镇静和深镇静的给药方案。
丙泊酚的药代动力学由一个三室模型描述,以瘦体重和脂肪体重作为协变量。丙泊酚的药效学由一个S形模型描述,将镇静概率与血浆丙泊酚浓度相关联。丙泊酚的药效学模型预测浅镇静和深镇静水平的准确率为73%。镇静评分2、3、4和5分对应的血浆丙泊酚浓度概率模式分别为0.25、0.6、1.0和2.0μg/ml。在典型受试者中,丙泊酚浅镇静(镇静评分 = 3→2)24小时、72小时、7天和14天后的预测苏醒时间分别为13、34、198和203分钟。丙泊酚深镇静(镇静评分 = 5→2)对应的苏醒时间分别为25、59、71和74小时。
ICU患者丙泊酚镇静后的苏醒时间随镇静深度、镇静持续时间和患者身体状况而变化。维持浅镇静水平可确保长期给予丙泊酚后快速苏醒。